Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Short-term Investments (2016 - 2022)

Catalyst Pharmaceuticals' Short-term Investments history spans 12 years, with the latest figure at $9.9 million for Q2 2022.

  • For Q2 2022, Short-term Investments fell 50.57% year-over-year to $9.9 million; the TTM value through Jun 2022 reached $9.9 million, down 50.57%, while the annual FY2021 figure was $19.8 million, 97.4% up from the prior year.
  • Short-term Investments reached $9.9 million in Q2 2022 per CPRX's latest filing, down from $19.4 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $58.5 million in Q2 2018 to a low of $5.0 million in Q4 2019.
  • Average Short-term Investments over 5 years is $26.8 million, with a median of $20.0 million recorded in 2021.
  • Peak YoY movement for Short-term Investments: surged 120.44% in 2018, then crashed 86.44% in 2019.
  • A 5-year view of Short-term Investments shows it stood at $36.9 million in 2018, then plummeted by 86.44% to $5.0 million in 2019, then soared by 100.54% to $10.0 million in 2020, then skyrocketed by 97.4% to $19.8 million in 2021, then tumbled by 50.17% to $9.9 million in 2022.
  • Per Business Quant, the three most recent readings for CPRX's Short-term Investments are $9.9 million (Q2 2022), $19.4 million (Q1 2022), and $19.8 million (Q4 2021).